Pharmaceutical Industry Examines China R&D Strategy Amidst Financial Crisis
This article was originally published in PharmAsia News
In the face of sliding profit margins and imminent drug patent expiry, multinational drug firms are seeking different avenues such as investing in or buying biotech firms to acquire new drugs. Sanofi-Aventis does not discount such possibilities but advocates collaboration as a better model to retain talent and technology. The company recently established a partnership with the Shanghai Institute for Biological Sciences (PharmAsia News Oct. 23, 2008) to cooperate with local academic institutes instead of setting up its own R&D center. According to Sanofi officials, the firm's R&D investment this year will be flat or even decrease slightly. (Click here for more - Chinese Language)
You may also be interested in...
France's Sanofi-Aventis plans to use a new agreement with the Shanghai Institute for Biological Sciences to expand its research and development facility and step up that work in China. The agreement calls for a focus on discovering and developing drugs to treat cancer, diabetes, and problems of the nervous systems. The agreement in Shanghai coincides with completion by the end of this year of the firm's biometrics center in Beijing, aimed at providing support for global and local clinical trials. (Click here for more
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.